Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012
Review of NICE Technology Appraisal Guidance No.174; Rituximab for the first line treatment of chronic lymphocytic leukaemia, and No.193; Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
Decision to defer the review
In December 2010, the consideration of a review of TA174 and TA193 was deferred until during 2012 so that the results from the ongoing trial MO20927 could be taken into account. The results of this trial are not likely to be published until early in 2013.
Consequently we have decided to defer the consideration of the review, and will consult on our plans for TA174 and TA193 within six months of the publication of MO20927.
This page was last updated: 01 October 2012